Desarrollo de un aula virtual para el mejoramiento del aprendizaje de alumnos de aulas de apoyo a nivel nacional

El presente documento está conformado por cinco capítulos, en los cuales se ha desarrollado un aula virtual para el mejoramiento del aprendizaje de alumnos que asisten a las aulas de apoyo, con lo que se pretende; que los alumnos puedan practicar aquellos temas en los que han tenido dificultad al estudiarlos en las aulas regulares, ya sea por diferentes circunstancias; podrán realizar además las evaluaciones con el propósito de identificar los avances obtenidos. Por último se ha creado un sistema administrativo, para que el docente pueda llevar los registros necesarios a la hora de ingresar el alumno a la aula de apoyo por medio de esta nueva herramienta, facilitando y mejorando los procesos anteriores. CAPITULO I.: Se describen las generalidades del proyecto en el cual se exponen los objetivos, alcances, limitaciones y justificación del proyecto, planteamiento del problema, antecedentes de la escuela, de las aulas de apoyo y de FUNPRES, y por último la situación actual de la institución y las unidades involucradas. CAPITULO II. Se detalla el marco teórico, donde se presentan los conceptos más importantes relacionados con las aulas virtuales y las plataformas pedagógicas, además se presentan información sobre la historia y evolución del lenguaje de programación Asp.Net por último el diseño y normalización de las bases de datos. CAPITULO III. Se presenta la investigación realizada a través de las entrevistas, encuestas, para los requerimientos del sistema. CAPITULO IV. En el presente capitulo se muestrea el diseño de la plataforma virtual, y el diseño y desarrollo del sistema administrativo, se muestra la factibilidad del proyecto operativo, técnico y económico, el cual tiene como finalidad conocer si el proyecto es factible, para poder realizar un cuadro de selección de herramienta para conocer el software apropiado para el desarrollo del mism

Márgenes brutos de producción de tomate bajo invernadero: campaña 2021

Se presenta una estimación de los Márgenes Brutos (MB) de la producción hortícola de tomate hibrido Elpida bajo invernadero de la zona de Goya-Lavalle (Corrientes) para la campaña 2021, con el objetivo de actualizar la publicación realizada en noviembre de 2020.EEA Bella VistaFil: Zoilo, Oscar José. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Bella Vista. Agencia de Extensión Rural Goya; Argentina.Fil: Bernardi, María Julia. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Bella Vista. Agencia de Extensión Rural Goya; Argentina.Fil: Aguirre Estrada, José María. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Bella Vista. Agencia de Extensión Rural Goya; Argentina.Fil: Pacheco, Roberto Matías. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Bella Vista; ArgentinaFil: Obregón, Verónica Gabriela. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Bella Vista; Argentin

Márgenes brutos de producción de tomate bajo invernadero: campaña 2020

Se presenta una estimación de los Márgenes Brutos (MB) de la producción hortícola de tomate Elpida bajo invernadero de la zona de Goya-Lavalle (Corrientes) para la campaña 2020.EEA Bella VistaFil: Zoilo, Oscar Jose. Instituto Nacional de Tecnología Agropecuaria (INTA). Agencia de Extensión Rural Goya; ArgentinaFil: Bernardi, Maria Julia. Instituto Nacional de Tecnología Agropecuaria (INTA). Agencia de Extensión Rural Goya; ArgentinaFil: Aguirre Estrada, Jose Maria. Instituto Nacional de Tecnología Agropecuaria (INTA). Agencia de Extensión Rural Goya; ArgentinaFil: Pacheco, Roberto Matias. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Bella Vista; ArgentinaFil: Molina, Nestor Albino. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Bella Vista; Argentin

Single-cell transcriptional profile of CD34+ hematopoietic progenitor cells from del(5q) myelodysplastic syndromes and impact of lenalidomide

While myelodysplastic syndromes with del(5q) (del(5q) MDS) comprises a well-defined hematological subgroup, the molecular basis underlying its origin remains unknown. Using single cell RNA-seq (scRNA-seq) on CD34 + progenitors from del(5q) MDS patients, we have identified cells harboring the deletion, characterizing the transcriptional impact of this genetic insult on disease pathogenesis and treatment response. Interestingly, both del(5q) and non-del(5q) cells present similar transcriptional lesions, indicating that all cells, and not only those harboring the deletion, may contribute to aberrant hematopoietic differentiation. However, gene regulatory network (GRN) analyses reveal a group of regulons showing aberrant activity that could trigger altered hematopoiesis exclusively in del(5q) cells, pointing to a more prominent role of these cells in disease phenotype. In del(5q) MDS patients achieving hematological response upon lenalidomide treatment, the drug reverts several transcriptional alterations in both del(5q) and non-del(5q) cells, but other lesions remain, which may be responsible for potential future relapses. Moreover, lack of hematological response is associated with the inability of lenalidomide to reverse transcriptional alterations. Collectively, this study reveals transcriptional alterations that could contribute to the pathogenesis and treatment response of del(5q) MDS. The hematopoiesis of patients with del(5q) Myelodysplastic Syndromes is composed of a mixture of cells with and without the deletion. Here, the authors show that del(5q) and non-del(5q) cells share similar transcriptional alterations, with del(5q) cells presenting additional lesions. Moreover, hematological response to lenalidomide is associated with the reversal of some transcriptional lesions in both del(5q) and non-del(5q) cells

The ocean sampling day consortium.

Ocean Sampling Day was initiated by the EU-funded Micro B3 (Marine Microbial Biodiversity, Bioinformatics, Biotechnology) project to obtain a snapshot of the marine microbial biodiversity and function of the world's oceans. It is a simultaneous global mega-sequencing campaign aiming to generate the largest standardized microbial data set in a single day. This will be achievable only through the coordinated efforts of an Ocean Sampling Day Consortium, supportive partnerships and networks between sites. This commentary outlines the establishment, function and aims of the Consortium and describes our vision for a sustainable study of marine microbial communities and their embedded functional traits

Actividad antioxidante, tóxica y antimicrobiana de Rosmarinus officinalis, Ruta graveolens y Juglans regia contra Helicobacter pylori

Helicobacter pylori is a Gram negative bacteria with ahigh prevalence worldwide, causing gastric and duodenal ulcers and cancer,  it is one of the main public health problems in Mexico. This work evaluates the in vitro antioxidant, toxic, antibacterial activity, and the ability to inhibit the biofilm formed by H. pylori, of the methanolic extract Juglans regia(EMJR) and crude ethanolic extracts of the species Rosmarinus officinalis (EERO) and Ruta graveolens (EERG) collected in the state of Nuevo León, Mexico. Through phytochemical screening, the presence of secondary metabolites was qualitatively determined. The antioxidant capacity by the DPPH method showed that EMJR was the most active with an IC50of 2.759 μg/mL. The EERG and EERO developed inhibition halos of 11 and 16 mm and a MIC of 0.136 and 0.51 mg/ mL respectively, only the EERO inhibits biofilm formation by 83.7%. Toxicity tests on Artemia salina showed weak to moderate toxicity. The results show the potential use of the studied extracts as alternative sources in the search for new treatments against H. pylori.Helicobacter pylori es una bacteria Gram negativa, con alta prevalencia a nivel mundial, la infección causa úlceras gástricas, duodenales y cáncer, se considera uno de los principales problemas de salud pública en México. El trabajo evalúa in vitro la actividad antioxidante, tóxica, antibacteriana yla capacidad de inhibir la biopelícula formada por H. pylori del extracto metanólico Juglans regia (EMJR) y los extractos etanólicos crudos de las especies Rosmarinus officinalis (EERO) y Ruta graveolens (EERG) colectadas en el estado de Nuevo León, México. Mediante tamizaje fitoquímico se determinócualitativamente la presencia de metabolitos secundarios. La capacidad antioxidante por el método de DPPH, mostró que el EMJR fue el más activo con una CI50 de 2.759 μg/mL. Los EERG y EERO desarrollaron halos de inhibición de 11 y 16 mm y una CMI de 0.136 y 0.51 mg/mL respectivamente, solo el EERO inhibe la formación de la biopelícula en un 83.7 %. Los ensayos de toxicidad sobre Artemia salina mostraron toxicidad de débil a moderada. Los demuestran el potencial uso de los extractos estudiados como fuentes alternativas en la búsqueda de nuevos tratamientos contra H. pylori

The ocean sampling day consortium

Ocean Sampling Day was initiated by the EU-funded Micro B3 (Marine Microbial Biodiversity, Bioinformatics, Biotechnology) project to obtain a snapshot of the marine microbial biodiversity and function of the world’s oceans. It is a simultaneous global mega-sequencing campaign aiming to generate the largest standardized microbial data set in a single day. This will be achievable only through the coordinated efforts of an Ocean Sampling Day Consortium, supportive partnerships and networks between sites. This commentary outlines the establishment, function and aims of the Consortium and describes our vision for a sustainable study of marine microbial communities and their embedded functional traits

Risk and outcomes of COVID-19 in patients with multiple sclerosis

Background and purpose Limited information is available on incidence and outcomes of COVID-19 in patients with multiple sclerosis (MS). This study investigated the risks of SARS-CoV-2 infection and COVID-19-related outcomes in patients with MS, and compared these with the general population. Methods A regional registry was created to collect data on incidence, hospitalization rates, intensive care unit admission, and death in patients with MS and COVID-19. National government outcomes and seroprevalence data were used for comparison. The study was conducted at 14 specialist MS treatment centers in Madrid, Spain, between February and May 2020. Results Two-hundred nineteen patients were included in the registry, 51 of whom were hospitalized with COVID-19. The mean age ± standard deviation was 45.3 ± 12.4 years, and the mean duration of MS was 11.9 ± 8.9 years. The infection incidence rate was lower in patients with MS than the general population (adjusted incidence rate ratio = 0.78, 95% confidence interval [CI] = 0.70–0.80), but hospitalization rates were higher (relative risk = 5.03, 95% CI = 3.76–6.62). Disease severity was generally low, with only one admission to an intensive care unit and five deaths. Males with MS had higher incidence rates and risk of hospitalization than females. No association was found between the use of any disease-modifying treatment and hospitalization risk. Conclusions Patients with MS do not appear to have greater risks of SARS-CoV-2 infection or severe COVID-19 outcomes compared with the general population. The decision to start or continue disease-modifying treatment should be based on a careful risk–benefit assessment.post-print996 K

The Fourteenth Data Release of the Sloan Digital Sky Survey: First Spectroscopic Data from the extended Baryon Oscillation Spectroscopic Survey and from the second phase of the Apache Point Observatory Galactic Evolution Experiment

The fourth generation of the Sloan Digital Sky Survey (SDSS-IV) has been in operation since July 2014. This paper describes the second data release from this phase, and the fourteenth from SDSS overall (making this, Data Release Fourteen or DR14). This release makes public data taken by SDSS-IV in its first two years of operation (July 2014-2016). Like all previous SDSS releases, DR14 is cumulative, including the most recent reductions and calibrations of all data taken by SDSS since the first phase began operations in 2000. New in DR14 is the first public release of data from the extended Baryon Oscillation Spectroscopic Survey (eBOSS); the first data from the second phase of the Apache Point Observatory (APO) Galactic Evolution Experiment (APOGEE-2), including stellar parameter estimates from an innovative data driven machine learning algorithm known as "The Cannon"; and almost twice as many data cubes from the Mapping Nearby Galaxies at APO (MaNGA) survey as were in the previous release (N = 2812 in total). This paper describes the location and format of the publicly available data from SDSS-IV surveys. We provide references to the important technical papers describing how these data have been taken (both targeting and observation details) and processed for scientific use. The SDSS website (www.sdss.org) has been updated for this release, and provides links to data downloads, as well as tutorials and examples of data use. SDSS-IV is planning to continue to collect astronomical data until 2020, and will be followed by SDSS-V.Comment: SDSS-IV collaboration alphabetical author data release paper. DR14 happened on 31st July 2017. 19 pages, 5 figures. Accepted by ApJS on 28th Nov 2017 (this is the "post-print" and "post-proofs" version; minor corrections only from v1, and most of errors found in proofs corrected

Spread of a SARS-CoV-2 variant through Europe in the summer of 2020

[EN] Following its emergence in late 2019, the spread of SARS-CoV-21,2 has been tracked by phylogenetic analysis of viral genome sequences in unprecedented detail3,4,5. Although the virus spread globally in early 2020 before borders closed, intercontinental travel has since been greatly reduced. However, travel within Europe resumed in the summer of 2020. Here we report on a SARS-CoV-2 variant, 20E (EU1), that was identified in Spain in early summer 2020 and subsequently spread across Europe. We find no evidence that this variant has increased transmissibility, but instead demonstrate how rising incidence in Spain, resumption of travel, and lack of effective screening and containment may explain the variant’s success. Despite travel restrictions, we estimate that 20E (EU1) was introduced hundreds of times to European countries by summertime travellers, which is likely to have undermined local efforts to minimize infection with SARS-CoV-2. Our results illustrate how a variant can rapidly become dominant even in the absence of a substantial transmission advantage in favourable epidemiological settings. Genomic surveillance is critical for understanding how travel can affect transmission of SARS-CoV-2, and thus for informing future containment strategies as travel resumes.S